Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2025-07-28 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Resignation of Statutory Auditor
Regulatory Filings
2025-07-28 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the change in statutory auditors of a material subsidiary of the company, Strides Arcolab International Limited, UK. It includes specifics about the auditor's resignation, appointment of a new auditor, reasons for the change, dates, and regulatory references to SEBI Listing Regulations. The content is focused on the auditor change event and related disclosures rather than a full audit report or financial statements. It is not an Annual Report, Audit Report, or Interim Report, but rather a regulatory announcement about auditor changes. This fits the category of Regulatory Filings (RNS) as it is a compliance disclosure under SEBI regulations and does not contain the audit report itself or detailed financial data. The document length and detail support a high confidence in this classification.
2025-07-28 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a communication from Strides Pharma Science Limited to shareholders reminding them about unclaimed dividends from the fiscal year 2017-2018 that are due to be transferred to the Investor Education and Protection Fund (IEPF) as per regulatory requirements. It references regulatory rules and provides instructions for shareholders to claim their dividends before a specified deadline. The document does not contain financial statements, earnings data, or detailed financial analysis. It is primarily a regulatory compliance announcement and shareholder notification regarding dividend claims and share transfers related to unclaimed dividends. The document length is 4856 characters, which is relatively short and consistent with a notification rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS) as it is a regulatory announcement and shareholder communication that does not fit into other specific categories like dividend notice or earnings release.
2025-07-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2025-07-23 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-07-23 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled Board Meeting to consider and approve the un-audited financial results for the quarter ended June 30, 2025. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about board meetings. The document does not contain the financial results themselves but is an announcement of the upcoming board meeting where such results will be approved. The document length is short (1787 characters) and serves as an intimation rather than a report. Therefore, it is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release, which would require actual financial data or results.
2025-07-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.